Clinical and immunological factors in emphysema progression: Five-year prospective longitudinal exacerbation study of chronic obstructive pulmonary disease (LES-COPD)

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 10, 2015, Pages 1171-1178

  Bhavani, Sivasubramanium ^a   Tsai, Chu Lin ^b,c   Perusich, Sarah ^a   Hesselbacher, Sean ^a   Coxson, Harvey ^d   Pandit, Lavannya ^a,e   Corry, David B ^a,e   Kheradmand, Farrah ^a,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Emphysema progression; IFN g; IL 17; IL 6; T cells

Indexed keywords

ELASTIN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; CYTOKINE;

6 MINUTE WALK DISTANCE; ADULT; ARTICLE; BLOOD; BODY MASS; CD4+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; CYTOKINE RESPONSE; DISEASE COURSE; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTION TEST; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; COMPLICATION; EXERCISE TEST; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE;

ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDIES; CYTOKINES; DISEASE PROGRESSION; EMPHYSEMA; EXERCISE TEST; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; T-LYMPHOCYTES;

EID: 84949035984     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201504-0736OC     Document Type: Article

References (34)

1. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, Ockene JK, Prentice RL, Speizer FE, Thun MJ, et al. Smoking and mortality: beyond established causes. N Engl J Med 2015;372: 631-640.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Plos Med 2006;3: e442.
3. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008;178: 738-744.
4. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009;101: 554-559.
5. Vestbo J. COPD: definition and phenotypes. Clin Chest Med 2014;35: 1-6.
6. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med 2014;108: 729-736.
7. Agusti A, Calverley PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11: 122.
8. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PMA, Coxson H, Crim C, et al.; ECLIPSE Study Investigators. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014;69: 666-672.
9. Vestbo J, Agusti A, Wouters EFM, Bakke P, Calverley PMA, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014;189: 1022-1030.
10. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99: 715-726.
11. Hesselbacher SE, Ross R, Schabath MB, Smith EO, Perusich S, Barrow N, Smithwick P, Mammen MJ, Coxson H, Krowchuk N, et al. Crosssectional analysis of the utility of pulmonary function tests in predicting emphysema in ever-smokers. Int J Environ Res Public Health 2011;8: 1324-1340.
12. Spaggiari E, Zompatori M, Verduri A, Chetta A, Bnà C, Ormitti F, Sverzellati N, Rabaiotti E. Early smoking-induced lung lesions in asymptomatic subjects: correlations between high resolution dynamic CT and pulmonary function testing. Radiol Med (Torino) 2005;109: 27-39.
13. Xu C, Hesselbacher S, Tsai C-L, Shan M, Spitz M, Scheurer M, Roberts L, Perusich S, Zarinkamar N, Coxson H, et al. Autoreactive T cells in human smokers is predictive of clinical outcome. Front Immunol 2012;3: 267.
14. Tsai CL, Garcia JM, Perusich S, Coxson H, Krowchuk N, Corry DB, Kheradmand F. Factors associated with progression of emphysema quantified by CT scan in ever smokers: the 5-year prospective LESCOPD study. Am J Respir Crit Care Med 2014;189: A5105.
15. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162: 167-173.
16. Singh M, Lee SH, Porter P, Xu C, Ohno A, Atmar RL, Greenberg SB, Bandi V, Gern J, Amineva S, et al. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010;125: 1369-1378.e2.
17. Crapo R, Enright P, Zeballos J; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166: 111-117.
18. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26: 948-968.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159: 179-187.
20. Stocks J, Quanjer PH; Official Statement of the European Respiratory Society. Reference values for residual volume, functional residual capacity and total lung capacity: ATS Workshop on Lung Volume Measurements. Eur Respir J 1995;8: 492-506.
21. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013;1: 129-136.
22. Coxson HO, Lam S. Quantitative assessment of the airway wall using computed tomography and optical coherence tomography. Proc Am Thorac Soc 2009;6: 439-443.
23. Shan M, Cheng HF, Song LZ, Roberts L, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Storness-Bliss C, et al. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci Transl Med 2009;1: 4ra10.
24. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7: 32-43.
25. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. Plos Med 2004;1: e8.
26. Kheradmand F, Shan M, Xu C, Corry DB. Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence. Expert Rev Clin Immunol 2012;8: 285-292.
27. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272: 1497-1505.
28. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, et al.; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365: 1184-1192.
29. He JQ, Foreman MG, Shumansky K, Zhang X, Akhabir L, Sin DD, Man SFP, DeMeo DL, Litonjua AA, Silverman EK, et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 2009; 64: 698-704.
30. Yuan X, Shan M, You R, Frazier MV, Hong MJ, Wetsel RA, Drouin S, Seryshev A, Song LZ, Cornwell L, et al. Activation of C3a receptor is required in cigarette smoke-mediated emphysema. Mucosal Immunol 2015;8: 874-885.
31. Shan M, You R, Yuan X, Frazier MV, Porter P, Seryshev A, Hong J-S, Song LZ, Zhang Y, Hilsenbeck S, et al. Agonistic induction of PPARg reverses cigarette smoke-induced emphysema. J Clin Invest 2014; 124: 1371-1381.
32. Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, Lomas DA, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014;69: 718-723.
33. Lahousse L, van den Bouwhuijsen QJA, Loth DW, Joos GF, Hofman A, Witteman JCM, van der Lugt A, Brusselle GG, Stricker BH. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med 2013; 187: 58-64.
34. Patel BD, Loo WJ, Tasker AD, Screaton NJ, Burrows NP, Silverman EK, Lomas DA. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006;61: 568-571.